Company
Daiichi Sankyo
Tokyo-based pharmaceutical company formed in a 2005 merger of Sankyo (founded 1899) and Daiichi Pharmaceutical (founded 1915); originated the DXd antibody-drug conjugate platform behind Enhertu, developed with AstraZeneca.
1 story
Regulatory News has published 1 story about Daiichi Sankyo on 4 October 2026, sourced to the primary record — the regulator’s decision, the company’s filing or its own announcement. This page is generated from that coverage. Last updated 4 October 2026.
This page is generated from Regulatory News’ editorial coverage of Daiichi Sankyo. It is not an advertisement.
Products in our coverage
Our coverage
